A Phase II Study of AZD2171 in Recurrent Glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Cediranib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Jun 2017 Converging evidence from 5 seperate phase II trials (NCT00035656, NCT00345163, NCT00704288, NCT00369590 and NTR1929) results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 21 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.